QIAGEN’s common share price varied widely during 2020, although it closed the year significantly higher in both the U.S. and European markets. The performance was influenced by the unsuccessful tender offer for QIAGEN to be acquired, the effects of the COVID-19 pandemic and initiatives to expand the business post-pandemic. QIAGEN’s senior executives and Investor Relations team have been recognized for proactive, transparent communications with the financial community. QIAGEN’s Investor Relations was ranked second overall in Institutional Investor magazine’s 2020 European small- and mid-cap survey. We thank shareholders for their continued support.